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MUSCLE CONTRACTIONS, exercise, treatment with the adenosine analog 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside (AICAR), and exposure to hypoxic conditions all increase the sensitivity of skeletal muscle glucose transport to stimulation by insulin (2, 7, 11, 16, 22, 36) . A factor shared by all of these insulin-sensitizing treatments is that they activate the AMP-activated protein kinase (AMPK) (7, 35) , leading to the suggestion that AMPK activation mediates increased insulin action (7, 16) . However, a causative link between AMPK and insulin sensitivity has not yet been determined.
Well-known effects of chronic AICAR treatment include increased muscle cell expression of GLUT4 (20, 30, 31, 43) , the contraction-and insulin-regulated glucose transporter, and a secondary increase in insulin-stimulated glucose transport that is directly related to the increase in cellular GLUT4 protein content (19, 30) . However, after a single treatment of muscle with AICAR, insulin sensitivity is enhanced, even when protein synthesis is prevented (7) . Thus the acute increase in insulin action after a single AICAR treatment, just like the insulin sensitivity that occurs after a single bout of exercise (32) , is a process that is independent of changes in GLUT4 protein content.
The aim of our study was evaluate the role of AMPK in acute (i.e., over a few hours) regulation of insulin action. We examined the effects of AMPK-activating stimuli on insulinstimulated glucose transport in insulin-responsive C 2 C 12 myotubes. We hypothesized that pretreatment of cells with AICAR or hyperosmotic stress [another AMPK activator (9) ] would increase insulin-stimulated glucose transport concomitant with increased phosphorylation of AMPK. We further hypothesized that inhibition of AMPK would prevent development of insulin sensitivity after exposure of cells to hyperosmotic stress. We selected the hyperosmotic stress treatment, because it, unlike AICAR incubation, is a suitable model for use with the AMPK inhibitor compound C (9) .
MATERIALS AND METHODS
Materials. FBS and antibiotic/antimycotic solution (10,000 U penicillin/ml, 10 mg streptomycin/ml, 0.025 mg fungizone/ml) were from Gemini Bio-Products (Woodland, CA). Cell culture dishes were from Fisher Scientific (Hanover Park, IL). Purified porcine insulin was from Eli Lilly (Indianapolis, IN).
3 H-labeled 2-deoxyglucose (2DG) was from American Radiolabeled Chemicals (St. Louis, MO). Sorbitol, wortmannin, and cytochalasin B were obtained from Sigma Chemical (St. Louis, MO), and AICAR was purchased from Toronto Research Chemicals (North York, ON). Indinavir and compound C were generously provided by Merck (Rahway, NJ). Iodotubercidin was purchased from EMD Biosciences (La Jolla, CA). Antibodies against AMPK, phosphorylated AMPK (pAMPK), and phosphorylated acetyl-CoA carboxylase (pACC) were from Cell Signaling Technology (Beverly, MA). The pAMPK antibody is directed toward Thr 172 of the catalytic subunit of AMPK, and phosphorylation of AMPK at this site activates the kinase (5, 14) . Antibodies against ␤-tubulin that were used to demonstrate equal loading among lanes for pACC blots were from Zymed Laboratories (San Francisco, CA).
C 2C12 culture. Mouse C2C12 myoblasts were purchased from the American Type Culture Collection (Rockville, MD). Cells were cultured (39) in 100-mm polystyrene culture dishes in ␣-MEM supplemented with 10% FBS and 1% antibiotic antimycotic mixture and passaged by trypsinization using 0.25% trypsin. Cells were maintained in a humidified incubator under an atmosphere of 5% CO 2 at 37°C. Fresh medium was supplied every 24 h. For differentiation of myoblasts into myotubes, cells were seeded ϳ2 ϫ 10 4 cells/cm 2 in 24-well plates for 2DG uptake assays and in 6-well or 12-well plates for Western blotting. Differentiating cells were fed every 24 h for 3 days with ␣-MEM containing 2% horse serum, 1% antibiotic antimycotic mixture, and 10 Ϫ7 M insulin. Thereafter, differentiation continued with ␣-MEM containing 2% horse serum and 1% antibiotic antimycotic mixture (but no insulin) for the next 3 days before experiments were conducted. Insulin was included in the initial differentiation medium, because it has been reported that insulin stimulates myogenesis in L6 and C 2C12 myoblasts (26, 41) . In our hands, C2C12 myotubes that have been differentiated in media lacking insulin are not insulin responsive.
Effects of wortmannin and indinavir on insulin-stimulated glucose transport. For initial experiments, myotubes were serum starved for 12 h before glucose transport assays.
3 H-labeled 2DG uptake was measured in myotubes as described by Somwar et al. (39) . Timelines for experimental protocols are included in Figs. 1-6 . Incubations were performed in HEPES-buffered saline (HBS) solution (20 mM HEPES, pH 7.4, 140 mM NaCl, 5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl2) containing 5 mM glucose (40) . In some experiments, cells were incubated for 20 min in HBS with 100 nM wortmannin, a phosphatidylinositol-3 kinase (PI3K) inhibitor, in 0.1% DMSO or with vehicle before a 20-min exposure to 0 or 100 nM insulin. Glucose transport assays in the absence or presence of 100 nM insulin were performed as described below. Some cells were incubated for 10 min with 100 M indinavir (37) after initial exposure to insulin but before glucose transport assays were performed. Indinavir is a human immunodeficiency virus (HIV) protease inhibitor that also inhibits glucose transport through GLUT4 and thus is a tool to assess the functional contribution of GLUT4 to insulin-dependent glucose influx (28, 29, 37) .
Determination of 2DG transport rates. Before glucose transport assays, cells were rinsed twice with glucose-free HBS. Following the rinses, cells were incubated at room temperature for 10 min in 200 l of glucose-free HBS containing 3 H-labeled 2DG (3 Ci/ml), 10 M 2DG, and insulin or inhibitors if they had been present for the previous steps. Nonspecific 2DG uptake was determined by quantitation of cell-associated radioactivity in the presence of 10 M cytochalasin B, which blocks transporter-mediated glucose uptake. After incubation with the transport medium, the medium was aspirated rapidly, and the cells were immediately washed three times with ice-cold 0.9% saline before lysis in 0.2 N NaOH containing 0.2% SDS. Aliquots of cell lysates were saved for the determination of protein content by the bicinchoninic acid assay (Pierce, Rockford, IL). Samples were neutralized and then were counted for 3 H in a Packard TopCount liquid scintillation plate reader (PerkinElmer, Boston, MA).
Insulin action after treatment with AICAR. For insulin sensitivity experiments, myotubes were deliberately not serum starved, because serum starvation itself is a means of increasing insulin sensitivity of myotubes (24) . Additionally, 2% horse serum was present during AICAR treatments, because it has been found that the presence of serum during AICAR incubations, hypoxia, or muscle contractions is essential to the development of insulin sensitivity (7, 11) . In some experiments, cells were pretreated with 2 mM AICAR for 1 h before they were allowed to recover for 2 h in medium containing 2% horse serum. In a second set of experiments, cells were allowed to recover in serum-free medium after AICAR treatments. After the recovery incubations, glucose transport assays in the presence of 0, 10, or 100 nM insulin were performed as described above.
Insulin action after exposure to hyperosmotic stress. To assess the effects of hyperosmotic stress on insulin action, myotubes were incubated for 1 h in standard medium containing 2% horse serum (as described above) or the same medium made hyperosmotic by the addition of 0.6 M sorbitol. Incubation of mouse myotubes in hyperosmotic media has been shown to activate AMPK (9) . After the 1-h incubation, cells were allowed to recover for 2 h in serum-free medium before glucose transport assays in the absence or presence of 10 nM insulin, as described above. For cells exposed to insulin after incubation in normal or hyperosmotic medium, inhibition of insulinstimulated glucose transport by indinavir was determined, as described above.
To examine a role for AMPK in mediation of the increased insulin action after hyperosmotic stress, some myotubes were incubated with 20 M compound C before, during, and after incubation in hyperosmotic media. Compound C is a fairly specific inhibitor of AMPK (3, 9, 45) . Parallel experiments were performed with 50 M iodotubercidin, which has been demonstrated to inhibit AMPK in vitro (15) and prevent activation of AMPK by cyanide in cardiac myocytes (38) .
Immediate effects of hyperosmotic medium on glucose transport. Myotubes were serum starved for 12 h before incubation in the absence or presence of 0.6 M sorbitol in serum-free ␣-MEM for 30 min. Myotubes (Ϯ0.6 M sorbitol) were then immediately preincubated for 20 min in the absence or presence of 10 nM insulin before glucose transport assays (Ϯ0.6 M sorbitol, Ϯinsulin), as described above. Additional glucose transport assays (Ϯ0.6 M sorbitol, Ϯinsu-lin) were performed without serum starvation and for which all media contained 2% horse serum.
Western blot analysis. Myotubes were incubated for 30 min in the absence or presence of 2 mM AICAR or 600 mM sorbitol. Additional myotubes were incubated for 30 min in the absence or presence of kinase inhibitors (20 M compound C or 10 M iodotubercidin) and then for 30 min in medium Ϯkinase inhibitors and Ϯ0.6 M sorbitol. Cells were rinsed with HBS, scraped in ice-cold buffer containing phosphatase and protease inhibitors (50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2, 1 mM EDTA, 10 mM sodium pyrophosphate, 100 mM NaF, 2 mM Na3VO4, 10 g/ml aprotinin, 10 g/ml leupeptin, 0.5 g/ml pepstatin, and 2 mM PMSF), homogenized in Kontes ground glass tubes, and centrifuged for 10 min at 14,000 g. Supernatants were subjected to Western blot analysis of AMPK, pAMPK, pACC, or ␤-tubulin (to demonstrate equal loading among lanes for pACC blots).
Statistical analysis. One-or two-way analyses of variance were performed. Post hoc comparisons were performed with Fisher's protected least significance difference tests. For Western blot data, t-tests were used to compare values for sorbitol-and AICAR-treated cells with values for control cells. A level of P Ͻ 0.05 was set for significance for all tests, and all values are expressed as means Ϯ SE. Statistics were performed with SPSS (Chicago, IL) software, version 10.0.
RESULTS
Insulin-stimulated glucose uptake in C 2 C 12 myotubes. Insulin (100 nM) increased glucose uptake up to twofold in C 2 C 12 myotubes (Fig. 1) . This insulin-stimulated increase in glucose transport was likely to be mediated by GLUT4 (Fig. 1A) , as demonstrated by prevention of insulin action in myotubes in the presence of indinavir, a HIV protease inhibitor that also prevents glucose transport mediated by GLUT4, but not GLUT1 (37) . As shown in Fig. 1B , wortmannin prevented stimulation of glucose transport by insulin, suggesting that the increase in 2DG uptake is mediated by PI3K activation. These data are important in establishing that, under the culture conditions described, C 2 C 12 myotubes are insulin responsive, and the increased glucose transport stimulated by insulin appears to be dependent on GLUT4. Others have reported that insulin does not stimulate glucose transport in C 2 C 12 myotubes and that C 2 C 12 myotubes might not be an appropriate model for GLUT4-mediated glucose uptake (42) . However, these issues do not appear to be applicable under the culture conditions of the present study.
Insulin action after pretreatment with AICAR. Figure 2A shows that treatment with AICAR followed by a 2-h recovery in the presence of serum increased glucose transport in the presence of 10 nM insulin (P Ͻ 0.05). Also shown in Fig. 2A , AICAR pretreatment increased glucose transport in the presence of 100 nM insulin by about threefold (P Ͻ 0.05) over myotubes that were treated with AICAR but not insulin. AICAR pretreatment by itself raised the rate of 2DG uptake above baseline by ϳ35%. Figure 2B shows that AICAR pretreatment followed by a 2-h recovery in serum-free media and exposure to 10 nM insulin increased glucose transport Ͼ100% above basal transport (P Ͻ 0.05), despite no separate effect of 10 nM insulin on glucose transport.
Insulin action after incubation in hyperosmotic medium.
Hyperosmotic stress (Fig. 3) caused by inclusion of 0.6 M sorbitol in the incubation medium acted synergistically with 10 nM insulin to promote glucose transport (P Ͻ 0.001). There were no separate (i.e., unrelated to synergistic action) effects of either 10 nM insulin or pretreatment in hyperosmotic medium on glucose transport. The stimulation of glucose transport caused by 10 nM insulin after treatment with hyperosmotic medium was abolished by 20 M compound C, an AMPK inhibitor, suggesting that AMPK plays a role in potentiation of insulin action. Indinavir prevented the synergistic effects of Fig. 1 . Insulin-stimulated glucose transport in C2C12 myotubes is dependent on GLUT4 and phosphatidylinositol 3-kinase. A: C2C12 myotubes were incubated for 20 min in the absence (Ϫ) or presence (ϩ) of 100 nM insulin followed by a 30-min incubation in the absence or presence of 100 nM indinavir before assays for glucose transport. Indinavir, a human immunodeficiency virus protease inhibitor, prevents glucose transport mediated by GLUT4. Values are means Ϯ SE. *Significantly different from the 3 other groups (control, indinavir only, insulin ϩ indinavir), P Ͻ 0.05; n ϭ 24/group. B: C2C12 myotubes were incubated for 30 min in the absence or presence of 100 nM wortmannin (a phosphatidylinositol 3-kinase inhibitor) followed by a 20-min incubation in the absence or presence of 100 nM insulin before glucose transport assays. If wortmannin was present in the initial incubation, its presence was continued throughout subsequent incubations. Values are means Ϯ SE. †Significantly different from the 3 other groups (control, wortmannin only, insulin ϩ wortmannin), P Ͻ 0.05; n ϭ 6/group. 2DG, 2-deoxyglucose. Fig. 2 . 5-Aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside (AICAR) increases insulin sensitivity. Myotubes were incubated for 1 h in incubation media containing 2% horse serum and in the absence or presence of 2 mM AICAR. A: after AICAR treatment, cells were allowed to recover for 2 h in media containing serum. B: after AICAR treatment, cells were allowed to recover for 2 h in the absence of serum. After recovery, glucose transport assays followed a 20-min incubation in the absence or presence of 10 or 100 nM insulin. Values are means Ϯ SE. *Significantly different from corresponding control group (i.e., without insulin), P Ͻ 0.05. †Significantly different from control in the presence of 2 mM AICAR, P Ͻ 0.05. ‡Significantly different from all other treatment groups, P Ͻ 0.05; n ϭ 12 (control), 12 (AICAR), 6 (AICAR ϩ 10 nM insulin), and 6 (AICAR ϩ 100 nM insulin). §Significantly greater than other groups in B, P Ͻ 0.05; n ϭ 6/group. insulin and hyperosmotic stress on glucose transport. This suggests that potentiation of insulin action by hyperosmotic stress is dependent on increased GLUT4-mediated glucose transport. Iodotubercidin, which has been shown to inhibit AMPK in vitro (15) and block AMPK activation in cardiac myocytes (38) , prevented the combined effects of insulin and hyperosmotic stress on glucose transport (Fig. 4) . Iodotubercidin did not interfere with glucose transport for cells exposed to insulin only (i.e., cells with no prior incubation in hyperosmotic medium).
Western blotting. Immunoreactivity for pAMPK (normalized to AMPK) was approximately two-to threefold greater (P Ͻ 0.05) in C 2 C 12 myotubes incubated in AICAR or sorbitol compared with control (Fig. 5A) . AMPK content of cells did not differ by treatment (data not shown). As shown in Fig. 5B , hyperosmotic stress caused an increase in phosphorylation of the AMPK target ACC, and this effect was prevented by compound C. Similarly, iodotubercidin prevented an increase in ACC phosphorylation for cells incubated in hyperosmotic media (Fig. 5C) .
Immediate effects of hyperosmotic medium on glucose transport. Glucose transport was stimulated when cells were in hyperosmotic medium (Fig. 6) , as has previously been described for myotubes (8) . However, insulin action was not increased in hyperosmotic medium. The lack of immediate (i.e., in the absence of a recovery period) additive and synergistic effects of hyperosmotic stress on insulin action is not surprising, as insulin action has previously been reported to be impaired during hyperosmotic stress (13) . Data shown in Fig.  5 are for experiments with serum-free medium. Results for media containing 2% horse serum were not qualitatively different (data not shown).
DISCUSSION
The new information provided by this study is that cultured myotubes appear to be an appropriate model for the study of AICAR-related insulin sensitivity, hyperosmotic stress acts synergistically with insulin to promote glucose transport, and inhibition of AMPK prevents potentiation of insulin action after exposure of myotubes to hyperosmotic stress.
As reported by Richter et al. (36) and Garetto et al. (12), exercise causes sensitivity of glucose transport to stimulation by insulin in skeletal muscle. It has been demonstrated in rat skeletal muscle that contractions, hypoxia, and treatment with AICAR induce insulin sensitivity and increase AMPK activity, suggesting that an increase in insulin sensitivity of muscle glucose transport is mediated by activation of AMPK (7, 16) .
AMPK is activated by AICAR following uptake of AICAR into skeletal muscle and conversion of AICAR to the AMP analog AICAR 5Ј-monophosphate (ZMP) (4). However, ZMP effects cannot be specifically attributed to activation of AMPK, as opposed to regulation of some other AMP-sensitive pathway. In the present study, we have used compound C and iodotubercidin to provide evidence for involvement of AMPK in potentiation of insulin action by hyperosmotic stress. The hyperosmotic stress model provides valuable information that cannot be obtained from the use of compound C or iodotuber- Fig. 3 . AMP-activated protein kinase (AMPK) mediates synergistic effects of hyperosmotic stress and insulin on glucose transport. Cells were incubated for 1 h in hyperosmotic medium (0.6 M sorbitol) in the presence of serum and allowed to recover for 2 h in the absence of serum. Before, during, and for 1 h after hyperosmotic stress treatments for one group of cells, an AMPK inhibitor (compound C) was included in incubation media. Glucose transport assays followed a 20-min incubation in the absence or presence of 10 nM insulin and, for some groups, an additional 10-min incubation in the presence of indinavir, a human immunodeficiency virus protease inhibitor that also prevents GLUT4-mediated glucose transport. Values are means Ϯ SE. *Significantly different from all other groups, P Ͻ 0.001. Fig. 4 . Iodotubercidin prevents the combined effects of insulin and hyperosmotic stress on glucose transport. Cells were incubated for 1 h in hyperosmotic medium (0.6 M sorbitol) in the presence of serum and allowed to recover for 2 h in the absence of serum. Before, during, and for 1 h after hyperosmotic stress treatments for one group of cells, iodotubercidin was included in incubation media. Glucose transport assays followed a 20-min incubation in the absence or presence of 10 nM insulin. Values are means Ϯ SE; n ϭ 6 -8/group. *Significant effect of inhibitor, P Ͻ 0.05. †Significantly greater than control value (i.e., without sorbitol or insulin), P Ͻ 0.05. ‡Greater than values for all other groups, P Ͻ 0.001. cidin with AICAR treatments. For example, in addition to their inhibition of AMPK, compound C prevents AICAR uptake into cells (9) , and iodotubercidin prevents both adenosine uptake and adenosine phosphorylation (33) . Either compound would thus prevent activation by AICAR of any signaling pathways regulated by ZMP. The hyperosmotic stress model would not be subject to such nonspecificity of compound C or iodotubercidin action (9) . However, comparison of AICAR and hyperosmotic stress treatments could provide mechanistic information important for future studies. For example, AICAR increases insulin action to a greater extent than hyperosmotic stress. This might be attributable by the different means of AMPK activation by AICAR (through phosphorylation and allosterically) and hyperosmotic stress (through phosphorylation but without allosteric activation) (6, 8 -10, 34) .
Compound C is competitive with ATP at the AMPK catalytic site and does not inhibit kinases related to AMPK, including Syk, PKC-, PKA, or JAK3 (45) . Compound C does not inhibit p38-␣ or p38-␤ (9), and it reportedly does not interfere with activity of LKB1 (3), the upstream kinase of AMPK. However, compound C does prevent cellular actions of LKB1, which is consistent with inhibition of AMPK by the compound (3) . Although there appears to be no information on the specificity of compound C against the two isoforms of the catalytic subunit of AMPK, compound C blocks AMPK actions (including phosphorylation of ACC) under conditions that activate AMPK in a variety of cell types (3, 21, 25, 44) . Actions of compound C are consistent with the effects of transfection of cells with dominant-negative forms of either AMPK-␣1 or AMPK-␣2 (17, 23, 25) . While the specificity of compound C for AMPK inhibition has not been well characterized, and iodotubercidin inhibits other kinases (27) in addition to AMPK (15) , prevention of hyperosmotic stress-related insulin sensitivity by these two unrelated compounds provides evidence for involvement of AMPK.
As described above, incubation of rat skeletal muscle with AICAR in the presence of serum increases the ability of insulin to stimulate glucose transport (7) . In an attempt to replicate this finding for human myotubes, Al-Khalili et al. (1) treated differentiated primary muscle cells in the absence or presence of 10 and 100% serum and 2 mM AICAR followed by glucose transport assays in the presence of 0, 1.2, and 18 nM insulin. They found that AICAR-treated cells displayed increased phosphorylation of AMPK and its substrate ACC. On the other hand, regardless of the insulin concentrations used, AICAR did not cause a significant increase in insulin-stimulated glucose transport. The authors (1) suggested the possibility that low levels of GLUT4 in the human myotubes could have limited the ability of AICAR to potentiate glucose transport (1) . The present study describes culture conditions under which AICAR-related insulin sensitivity is apparent in C 2 C 12 myotubes, and it seems possible that the culture conditions could be applicable to the study of AMPK-related potentiation of insulin action in other muscle cell lines or in primary muscle cells.
AMPK has been identified as a potential modifier of insulin signaling through phosphorylation of insulin receptor substrate 1 (IRS-1) on Ser 789 (18) . It has been demonstrated that treatment with AICAR rapidly leads to phosphorylation of IRS-1 on Ser 789 in C 2 C 12 myotubes, and this phosphorylation is linked to a 65% increase in insulin-stimulated IRS-1-associated PI3K activity (18) . Even though the effects of AICAR on insulin-stimulated glucose transport were not assessed in that study (18) , the results illustrate an interaction between AMPK and early insulin signaling that may underlie the effects of AMPK activation on insulin action.
In the present study, prevention of insulin-stimulated glucose transport in the C 2 C 12 myotubes in the presence of the wortmannin, a PI3K inhibitor (40) , suggests that insulin stimulation of glucose transport in these cells involves classical insulin-signaling pathways. Furthermore, the insulin-stimulated increase in glucose transport was prevented by indinavir, a HIV protease inhibitor that also blocks glucose transport mediated by GLUT4 (29, 37) . This suggests that, in the C 2 C 12 myotubes in this study, GLUT4 (and not some other transporter, such as GLUT1) is responsible for insulin-stimulated increases in glucose uptake. It has been previously reported that insulin does not stimulate glucose transport in C 2 C 12 myotubes and that GLUT4 appears unresponsive to insulin (42) . However, in the present study, C 2 C 12 myotubes are responsive to insulin in what appears to be a GLUT4-dependent fashion.
In conclusion, we have shown that AICAR and hyperosmotic stress increase insulin action in myotubes concomitant with phosphorylation of AMPK. Through the use of the AMPK inhibitor compound C, we have demonstrated involvement of AMPK in potentiation of insulin action by hyperosmotic stress, and we have presented a cultured myotube model suitable for characterization of potential pathways that contribute to sensitivity of glucose transport to stimulation by insulin.
